MCL Literature Feed

Preclinical models show the PI3K inhibitor idelalisib synergizes with the CDK4/6 inhibitor palbociclib, providing a rationale for a novel combination therapy in relapsed/refractory MCL.

This case report documents a rare presentation of mantle cell lymphoma as complete heart block from cardiac metastasis, highlighting a critical differential diagnosis for unexplained conduction abnormalities.

This case report describes the rare simultaneous occurrence of recurrent hepatocellular carcinoma and mantle cell lymphoma, highlighting the diagnostic and therapeutic challenges of managing co-existing malignancies.

Preclinical data shows the novel CTPS1 inhibitor STP-B has single-agent activity in high-risk MCL (blastoid, TP53-mutated) and synergizes with venetoclax by downregulating MCL1, offering a new combination strategy.

This large, real-world French database study on ibrutinib focuses exclusively on patients with CLL, providing no specific data or insights relevant to mantle cell lymphoma.

This case report details an extremely rare presentation of relapsed mantle cell lymphoma as an appendiceal volvulus, highlighting an unusual cause of acute abdominal pain requiring emergent surgery.

This case report describes the rare but life-threatening development of disseminated intravascular coagulation (DIC) in a patient with the typically indolent, asymptomatic leukemic non-nodal variant of MCL.

A high monocyte-to-platelet ratio (MPR ≥ 3) at diagnosis is a novel, independent prognostic biomarker for inferior progression-free survival in transplant-ineligible mantle cell lymphoma patients.

This review summarizes the evolving treatment landscape for relapsed/refractory MCL, highlighting survival gains from BTKi and CAR-T and outlining emerging therapies like bispecifics for multiply-refractory patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

This study identifies a rare CD5/SOX11 double-negative pleomorphic MCL, showing CCND1 rearrangement is the key feature to differentiate it from cyclin D1-positive DLBCL, ensuring correct diagnosis.

A rare case of MCL presenting as diffuse polyposis throughout the entire GI tract achieved complete response after R-CHOP followed by salvage chemotherapy plus ibrutinib, highlighting this unusual presentation.

This case report details the practical challenges and potential toxicities of administering CAR-T cell therapy to an elderly MCL patient with high tumor burden, informing management of this high-risk group.

This case report details a rare MCL presentation as intestinal intussusception, requiring surgical resection for diagnosis and initial management prior to systemic chemotherapy in a young patient.

This case report identifies life-threatening aplastic anemia as a rare but fatal toxicity of acalabrutinib in MCL, urging clinicians to consider it in patients developing pancytopenia.

This study analyzes molecular responses in exceptional responders to the BTKi tirabrutinib, aiming to identify biomarkers for deep, durable remissions in relapsed/refractory mantle cell lymphoma.

This paper outlines the diagnostic and treatment challenges of rare ocular and nasopharyngeal MCL, highlighting the necessity of a multidisciplinary approach for managing these extranodal presentations.

This review summarizes how molecular profiling (e.g., TP53) and MRD are reshaping MCL therapy by integrating novel agents into frontline care, personalizing treatment, and improving high-risk patient outcomes.

This meta-analysis of phase 2/3 trials quantifies venous thromboembolism risk after CAR-T therapy, providing crucial data to guide thromboprophylaxis strategies in MCL patients.

This review explains MCL's clinical heterogeneity through distinct molecular subtypes and genomic alterations like TP53, which serve as key prognostic biomarkers and guide development of novel therapies.

Analysis of the FIL MCL0208 trial shows that stem cell collection and subsequent hematological recovery are feasible and safe in young, fit MCL patients undergoing frontline autologous transplant consolidation.

For transplant-eligible MCL, substituting rituximab with obinutuzumab in chemo-immunotherapy induction and maintenance significantly improved MRD negativity, 5-year progression-free survival (83% vs 67%), and overall survival.

This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.

This case report describes a rare presentation of MCL with paraneoplastic membranous nephropathy, highlighting the need to consider MCL in the differential diagnosis of unexplained nephrotic syndrome.

This multicenter retrospective study analyzes real-world maintenance strategies in mantle cell lymphoma, providing evidence to guide treatment selection and duration after initial therapy.

Preclinical data show WEE1 inhibition synergizes with bortezomib by inducing mitotic pyroptosis, a novel cell death mechanism, suggesting a potential strategy to overcome proteasome inhibitor resistance in MCL.

This study of Burkitt Lymphoma reveals the key MCL oncogene SOX11 has a context-dependent function, with a transcriptional program and downstream effects differing from its established role in MCL.

This paper identifies a subset of MCL with IRTA1-positive reactive marginal zone expansion, highlighting a potential diagnostic pitfall for pathologists distinguishing it from marginal zone lymphoma.

This multicenter real-world study demonstrates that CAR-T therapy can be an effective treatment for MCL patients with secondary CNS involvement, a population with historically poor outcomes.

Preclinical data show combining a BCL-XL inhibitor with venetoclax overcomes resistance in MCL models, even in BIM-deficient cells, suggesting a new strategy for venetoclax-refractory patients.